Citation: Yishen Mao, Caifeng Zou, Yongjian Jiang, Deliang Fu. Erythrocyte-derived drug delivery systems in cancer therapy[J]. Chinese Chemical Letters, ;2021, 32(3): 990-998. doi: 10.1016/j.cclet.2020.08.048 shu

Erythrocyte-derived drug delivery systems in cancer therapy

Department of Pancreatic Surgery, Pancreatic Disease Institute, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China

yongjianjiang@fudan.edu.cn

surgeonfdl@163.com

Received Date: 20 July 2020
Revised Date: 26 August 2020
Accepted Date: 28 August 2020
Available Online: 31 August 2020

Figures(3)

As natural blood components, erythrocytes were good candidates for being used as drug delivery systems to improve the pharmacokinetics, biocompatibility and many other aspects of different drugs. The advantages brought by erythrocytes making erythrocyte-derived drug delivery systems, also known as erythrocyte carriers, suitable for various anti-cancer agents, especially newly invented agents like nanoparticles, which were characterized by their undesired systematic toxicity, anaphylactic reactions and poor biocompatibility. Current researches on erythrocyte carriers in cancer therapy showed inspiring results in four major aspects: cancer enzyme therapy, delivering chemotherapeutic agents, combining with nanoparticles, and several other anti-cancer agents for gene or immune therapy. This novel delivering system was now undergoing the translation process from laboratory to clinical practice. Erythrocyte carriers for cancer enzyme therapy have entered the stage of clinical trial and have showed promising outcomes, and others were still at pre-clinical stage. In summary, erythrocyte-derived drug delivery system might play an indispensable role in the management of cancer in the future.
- Erythrocytes,
- Drug delivery,
- Cancer therapy,
- Nanoparticles,
- Chemotherapy
1. [1]
  W. Chen, R. Zheng, P.D. Baade, et al., CA Cancer J. Clin. 66(2016) 115-132. doi: 10.3322/caac.21338
2. [2]
  F.M. Veronese, Biomaterials 22(2001) 405-417. doi: 10.1016/S0142-9612(00)00193-9
3. [3]
  M. Hamidi, A. Zarrin, M. Foroozesh, S. Mohammadi-Samani, J. Control. Release 118(2007) 145-160. doi: 10.1016/j.jconrel.2006.06.032
4. [4]
  C.H. Villa, D.B. Cines, D.L. Siegel, V. Muzykantov, Transfus. Med. Rev. 31(2016) 26-35.
5. [5]
  S. Banskota, P. Yousefpour, A. Chilkoti, Macromol. Biosci. 17(2017) 1600361. doi: 10.1002/mabi.201600361
6. [6]
  P.A. Oldenborg, A. Zheleznyak, Y.F. Fang, et al., Science 288(2000) 2051-2054. doi: 10.1126/science.288.5473.2051
7. [7]
  K. Kinosita, T.Y. Tsong, Nature 272(1978) 258-260. doi: 10.1038/272258a0
8. [8]
  S.J. Updike, R.T. Wakamiya, E.N.J. Lightfoot, Science 193(1976) 681-683. doi: 10.1126/science.821145
9. [9]
  G.M. Ihler, R.H. Glew, F.W. Schnure, Proc. Natl. Acad. Sci. U. S. A. 70(1973) 2663-2666. doi: 10.1073/pnas.70.9.2663
10. [10]
  K. Adriaenssens, D. Karcher, A. Lowenthal, H.G. Terheggen, Clin. Chem. 22(1976) 323-326. doi: 10.1093/clinchem/22.3.323
11. [11]
  C. Domenech, X. Thomas, S. Chabaud, et al., Brit. J. Haematol. 153(2011) 58-65. doi: 10.1111/j.1365-2141.2011.08588.x
12. [12]
  R.H. Fang, C.M.J. Hu, L. Zhang, Expert Opin. Biol. Th. 12(2012) 385-389. doi: 10.1517/14712598.2012.661710
13. [13]
  O.A. Skorokhod, T.T. Garmaeva, V.M. Vitvitsky, et al., Medical Sci. Monit. 10(2004) I55-64.
14. [14]
  M. Müller, L. Büchi, K. Woodtli, A. Haeberli, J.H. Beer, FEBS Lett. 468(2000) 115-119. doi: 10.1016/S0014-5793(00)01204-7
15. [15]
  K. Ganguly, T. Krasik, S. Medinilla, et al., J. Pharmacol. Exp. Ther. 312(2005) 1106-1113. doi: 10.1124/jpet.104.075770
16. [16]
  M. Tonetti, E. Zocchi, L. Guida, et al., Adv. Exp. Med. Biol. 326(1992) 307-317.
17. [17]
  U. Benatti, C. Polvani, L. Guida, E. Zocchi, A.D. Flora, Proc. Natl. Acad. Sci. U. S. A. 85(1988) 3145-3149. doi: 10.1073/pnas.85.9.3145
18. [18]
  C.H. Villa, A.C. Anselmo, S. Mitragotri, V. Muzykantov, Adv. Drug Deliver. Rev. 106(2016) 88-103. doi: 10.1016/j.addr.2016.02.007
19. [19]
  E. Briones, C.I. Colino, J.M. Lanao, J. Control. Release 125(2008) 210-227. doi: 10.1016/j.jconrel.2007.10.027
20. [20]
  J.B. Bachet, F. Gay, R. Maréchal, et al., Pancreas 44(2015) 1141-1147. doi: 10.1097/MPA.0000000000000394
21. [21]
  M. Hunault-Berger, T. Leguay, F. Huguet, et al., Am. J. Hematol. 90(2015) 811-818. doi: 10.1002/ajh.24093
22. [22]
  B.E. Bax, M.D. Bain, L.D. Fairbanks, et al., Eur. J. Haematol. 79(2007) 338-348. doi: 10.1111/j.1600-0609.2007.00927.x
23. [23]
  E.A. Kosenko, N.I. Venediktova, A.A. Kudryavtsev, et al., Biochem. Cell Biol. 86(2008) 469-476. doi: 10.1139/O08-134
24. [24]
  J.M. Hill, J. Roberts, E. Loeb, et al., JAMA 202(1967) 882-888. doi: 10.1001/jama.1967.03130220070012
25. [25]
  F.F. Becker, J.D. Broome, Science 156(1967) 1602-1603. doi: 10.1126/science.156.3782.1602
26. [26]
  D.A. Cooney, R.E. Handschumacher, Annu. Rev. Pharmacolog. 10(1970) 421-440. doi: 10.1146/annurev.pa.10.040170.002225
27. [27]
  M.C. Wu, G.K. Arimura, A.A. Yunis, Int. J. Cancer 22(1978) 728-733. doi: 10.1002/ijc.2910220615
28. [28]
  B. Zhang, L.W. Dong, Y.X. Tan, et al., Br. J. Cancer 109(2013) 14-23. doi: 10.1038/bjc.2013.293
29. [29]
  P.L. Lorenzi, J.N. Weinstein, Drug News Perspect. 22(2009) 61-64. doi: 10.1358/dnp.2009.22.1.1303819
30. [30]
  Y. Godfrin, F. Horand, R. Franco, et al., Expert Opin. Biol. Th. 12(2011) 127-133.
31. [31]
  P. Hammel, P. Fabienne, L. Mineur, et al., Eur. J. Cancer 124(2020) 91-101. doi: 10.1016/j.ejca.2019.10.020
32. [32]
  L. Chessa, V. Leuzzi, A. Plebani, et al., Orphanet J. Rare Dis. 9(2014) 5. doi: 10.1186/1750-1172-9-5
33. [33]
  V. Leuzzi, R. Micheli, D. D'Agnano, et al., Neurol. Neuroimmunol. Neuroinflamm. 2(2015) e98. doi: 10.1212/NXI.0000000000000098
34. [34]
  F.I. Ataullakhanov, V.M. Vitvitskiǐ, A.M. Zhabotinskiǐ, A.V. Pichugin, Biokhimiia 50(1985) 1733-1737.
35. [35]
  C.M.J. Hu, R.H. Fang, L. Zhang, Adv. Healthc. Mater. 1(2012) 537-547. doi: 10.1002/adhm.201200138
36. [36]
  A. Naqi, J.R. DeLoach, K. Andrews, W. Satterfield, M. Keeling, Biotechnol. Appl. Biochem. 10(1988) 365-372.
37. [37]
  R. Kravtzoff, C. Ropars, M. Laguerre, J.P. Muh, M. Chassaigne, J. Pharm. Pharmacol. 42(1990) 473-476.
38. [38]
  Y.M. Kwon, H.S. Chung, C. Moon, et al., J. Control. Release 139(2009) 182-189. doi: 10.1016/j.jconrel.2009.06.027
39. [39]
  H. He, J. Ye, Y. Wang, et al., J. Control. Release 176(2014) 123-132. doi: 10.1016/j.jconrel.2013.12.019
40. [40]
  R. Kravtzoff, P.H. Colombat, I. Desbois, et al., Eur. J. Clin. Pharmacol. 51(1996) 221-225. doi: 10.1007/s002280050187
41. [41]
  S.J. Updike, R.T. Wakamiya, J. Lab. Clin. Med. 101(1983) 679-691.
42. [42]
  M.H. Woo, L.J. Hak, M.C. Storm, et al., Leukemia 12(1998) 1527-1533. doi: 10.1038/sj.leu.2401162
43. [43]
  H.F. Oettgen, P.A. Stephenson, M.K. Schwartz, et al., Cancer 25(1970) 253-278. doi: 10.1002/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U
44. [44]
  S.J. Updike, Bibl. Haematol. 51(1985) 65-74.
45. [45]
  M. Keeling, W. Satterfield, K. Andrews, J.R. DeLoach, Biotechnol. Appl. Biochem. 12(1990) 331-335.
46. [46]
  M.J. Poznansky, M. Shandling, M.A. Salkie, J. Elliott, E. Lau, Cancer Res. 42(1982) 1020-1025.
47. [47]
  V.I. Avramis, S. Sencer, A.P. Periclou, et al., Blood 99(2002) 1986-1994. doi: 10.1182/blood.V99.6.1986
48. [48]
  X. Thomas, C.L. Jeune, Int. J. Hematologic Oncol. 5(2016) 11-25. doi: 10.2217/ijh-2016-0002
49. [49]
  P. Hammel, J.B. Bachet, I. El-Hariry, et al., J. Clin. Oncol. 35(2017)e15718. doi: 10.1200/JCO.2017.35.15_suppl.e15718
50. [50]
  C. Barton, J.R. DeLoach, Am. J. Vet. Res. 43(1982) 2210-2212.
51. [51]
  T. Kitao, K. Hattori, M. Takeshita, Experientia 34(1978) 94-95. doi: 10.1007/BF01921924
52. [52]
  R. Mukthavaram, G. Shi, S. Kesari, D. Simberg, J. Control. Release 183(2014) 146-153. doi: 10.1016/j.jconrel.2014.03.038
53. [53]
  A.D. Flora, U. Benatti, L. Guida, E. Zocchi, Proc. Natl. Acad. Sci. U. S. A. 83(1986) 7029-7033. doi: 10.1073/pnas.83.18.7029
54. [54]
  M. Tonetti, A.B. Astroff, W. Satterfield, et al., Am. J. Vet. Res. 52(1991) 1630-1635.
55. [55]
  U. Benatti, E. Zocchi, M. Tonetti, et al., Pharmacol. Res. 21(1989) 27-33.
56. [56]
  E. Zocchi, M. Tonetti, C. Polvani, et al., Proc. Natl. Acad. Sci. U. S. A. 86(1989) 2040-2044. doi: 10.1073/pnas.86.6.2040
57. [57]
  T. Kitao, K. Hattori, Cancer Res. 40(1980) 1351-1353.
58. [58]
  A. Gasparini, M. Tonetti, M. Tonetti, et al., Adv. Exp. Med. Biol. 326(1992) 299-304.
59. [59]
  R.C. Gaudreault, B. Bellemare, J. Lacroix, Anticancer Res. 9(1989) 1201-1205.
60. [60]
  A. Lejeune, M. Moorjani, C. Gicquaud, et al., Anticancer Res. 14(1994) 915-919.
61. [61]
  M. Moorjani, A. Lejeune, C. Gicquaud, et al., Anticancer Res. 16(1996) 2831-2836.
62. [62]
  A. Lejeune, P. Poyet, R.C. Gaudreault, C. Gicquaud, Anticancer Res. 17(1997) 3599-3603.
63. [63]
  J. Désilets, A. Lejeune, J. Mercer, C. Gicquaud, Anticancer Res. 21(2001) 1741-1747.
64. [64]
  P.R. Mishra, N.K. Jain, Drug Deliv. 7(2000) 155-159. doi: 10.1080/10717540050120197
65. [65]
  P.R. Mishra, N.K. Jain, Drug Deliv. 10(2003) 277-282. doi: 10.1080/drd_10_4_277
66. [66]
  Q. Fu, P. Lv, Z. Chen, et al., Nanoscale 7(2015) 4020-4030. doi: 10.1039/C4NR07027E
67. [67]
  L. Rao, Q.F. Meng, Q. Huang, et al., Adv. Healthc. Mater. 5(2016) 1420-1427. doi: 10.1002/adhm.201600303
68. [68]
  A. Kroll, R.H. Fang, L. Zhang, Bioconjugate Chem. 28(2016) 23-32.
69. [69]
  O.C. Farokhzad, R. Langer, Adv. Drug Deliver. Rev. 58(2006) 1456-1459. doi: 10.1016/j.addr.2006.09.011
70. [70]
  K. Greish, J. Fang, T. Inutsuka, A. Nagamitsu, H. Maeda, Clin. Pharmacokinet. 42(2003) 1089-1105. doi: 10.2165/00003088-200342130-00002
71. [71]
  F. Yang, C. Jin, S. Subedi, et al., Cancer Treat. Rev. 38(2012) 566-579. doi: 10.1016/j.ctrv.2012.02.003
72. [72]
  J.G. Piao, L. Wang, F. Gao, et al., ACS Nano 8(2014) 10414-10425. doi: 10.1021/nn503779d
73. [73]
  K. Knop, R. Hoogenboom, D. Fischer, U.S. Schubert, Angew. Chem. Int. Ed. 49(2010) 6288-6308. doi: 10.1002/anie.200902672
74. [74]
  C.M.J. Hu, L. Zhang, S. Aryal, et al., Proc. Natl. Acad. Sci. U. S. A. 108(2011) 10980-10985. doi: 10.1073/pnas.1106634108
75. [75]
  H. Zhou, Z. Fan, P.K. Lemons, H. Cheng, Theranostics 6(2016) 1012-1022. doi: 10.7150/thno.15095
76. [76]
  Y. Wang, Y. Liu, H. Luehmann, et al., ACS Nano 6(2012) 5880-5888. doi: 10.1021/nn300464r
77. [77]
  Y. Wang, K.C.L. Black, H. Luehmann, et al., ACS Nano 7(2013) 2068-2077. doi: 10.1021/nn304332s
78. [78]
  P.L. Rodriguez, T. Harada, D.A. Christian, et al., Science 339(2013) 971-975. doi: 10.1126/science.1229568
79. [79]
  R.H. Fang, C.M.J. Hu, K.N.H. Chen, et al., Nanoscale 5(2013) 8884-8888. doi: 10.1039/c3nr03064d
80. [80]
  C. Wang, X. Sun, L. Cheng, et al., Adv. Mater. 26(2014) 4794-4802. doi: 10.1002/adma.201400158
81. [81]
  L. Rao, B. Cai, L.L. Bu, et al., ACS Nano 11(2017) 3496-3505. doi: 10.1021/acsnano.7b00133
82. [82]
  S. Aryal, C.M.J. Hu, R.H. Fang, et al., Nanomedicine 8(2013) 1271-1280. doi: 10.2217/nnm.12.153
83. [83]
  B.T. Luk, R.H. Fang, C.M.J. Hu, et al., Theranostics 6(2016) 1004-1011. doi: 10.7150/thno.14471
84. [84]
  H. Ding, Y. Lv, D. Ni, et al., Nanoscale 7(2015) 9806-9815. doi: 10.1039/C5NR02470F
85. [85]
  D.M. Zhu, W. Xie, Y.S. Xiao, et al., Nanotechnology 29(2018) 084002. doi: 10.1088/1361-6528/aa9ca1
86. [86]
  D. Wang, H. Dong, M. Li, et al., ACS Nano 12(2018) 5241-5252. doi: 10.1021/acsnano.7b08355
87. [87]
  X. Liang, X. Ye, C. Wang, et al., J. Control. Release 296(2019) 150-161. doi: 10.1016/j.jconrel.2019.01.027
88. [88]
  Y. Guo, D. Wang, Q. Song, et al., ACS Nano 9(2015) 6918-6933. doi: 10.1021/acsnano.5b01042
89. [89]
  W. Ou, J.H. Byeon, Z.C. Soe, et al., Theranostics 9(2019) 6780-6796. doi: 10.7150/thno.37123
90. [90]
  T. Wang, Y. Luo, H. Lv, et al., ACS Appl. Mater. Inter. 11(2019) 45455-45466. doi: 10.1021/acsami.9b16637
91. [91]
  L. Rao, Q. Meng, L.L. Bu, et al., ACS Appl. Mater. Inter. 9(2017) 2159-2168. doi: 10.1021/acsami.6b14450
92. [92]
  N.C. Singha, T. Nekoroski, C. Zhao, et al., Mol. Cancer Ther. 14(2015) 523-532. doi: 10.1158/1535-7163.MCT-14-0580
93. [93]
  R.H. Fang, C.M.J. Hu, B.T. Luk, et al., Nano Lett. 14(2014) 2181-2188. doi: 10.1021/nl500618u
94. [94]
  D. Dehaini, X. Wei, R.H. Fang, et al., Adv. Mater. 29(2017) 1606209. doi: 10.1002/adma.201606209
95. [95]
  Y. Liu, X. Wang, B. Ouyang, et al., J. Mater. Chem. B 6(2018) 7033-7041. doi: 10.1039/C8TB02143K
96. [96]
  Y. Wang, Z. Luan, C. Zhao, C. Bai, K. Yang, Eur. J. Pharm. Sci. 142(2020) 105136. doi: 10.1016/j.ejps.2019.105136
97. [97]
  Q. Jiang, Y. Liu, R. Guo, et al., Biomaterials 192(2019) 292-308. doi: 10.1016/j.biomaterials.2018.11.021
98. [98]
  S. Gautam, B. Barna, T. Chiang, J. Pettay, S. Deodhar, J. Biol. Response Mod. 6(1987) 346-354.
99. [99]
  S.A. Rosenberg, J. Immunol. 192(2014) 5451-5458. doi: 10.4049/jimmunol.1490019
100. [100]
  D.H. Mitchell, G.T. James, C.A. Kruse, Biotechnol. Appl. Biochem. 12(1990) 264-275.
101. [101]
  A. Banz, M. Cremel, A. Mouvant, et al., J. Immunother. 35(2012) 409-417. doi: 10.1097/CJI.0b013e3182594352
102. [102]
  P. Huang, J. Zhao, C. Wei, et al., Biomater. Sci. 5(2016) 120-127.
1. [1]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840
2. [2]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763
3. [3]
  Keyang Li , Yanan Wang , Yatao Xu , Guohua Shi , Sixian Wei , Xue Zhang , Baomei Zhang , Qiang Jia , Huanhua Xu , Liangmin Yu , Jun Wu , Zhiyu He . Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation. Chinese Chemical Letters, 2024, 35(10): 109511-. doi: 10.1016/j.cclet.2024.109511
4. [4]
  Zhi Li , Shuya Pan , Yuan Tian , Shaowei Liu , Weifeng Wei , Jinlin Wang , Tianfeng Chen , Ling Wang . Selenium nanoparticles enhance the chemotherapeutic efficacy of pemetrexed against non-small cell lung cancer. Chinese Chemical Letters, 2024, 35(12): 110018-. doi: 10.1016/j.cclet.2024.110018
5. [5]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
6. [6]
  Bohan Chen , Liming Gong , Jing Feng , Mingji Jin , Liqing Chen , Zhonggao Gao , Wei Huang . Research advances of nanoparticles for CAR-T therapy in solid tumors. Chinese Chemical Letters, 2024, 35(9): 109432-. doi: 10.1016/j.cclet.2023.109432
7. [7]
  Wei Su , Xiaoyan Luo , Peiyuan Li , Ying Zhang , Chenxiang Lin , Kang Wang , Jianzhuang Jiang . Phthalocyanine self-assembled nanoparticles for type Ⅰ photodynamic antibacterial therapy. Chinese Chemical Letters, 2024, 35(12): 109522-. doi: 10.1016/j.cclet.2024.109522
8. [8]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
9. [9]
  Tong Tong , Lezong Chen , Siying Wu , Zhong Cao , Yuanbin Song , Jun Wu . Establishment of a leucine-based poly(ester amide)s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment. Chinese Chemical Letters, 2024, 35(12): 109689-. doi: 10.1016/j.cclet.2024.109689
10. [10]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
11. [11]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
12. [12]
  Yuanyi Zhou , Ke Ma , Jinfeng Liu , Zirun Zheng , Bo Hu , Yu Meng , Zhizhong Li , Mingshan Zhu . Is reactive oxygen species the only way for cancer inhibition over single atom nanomedicine? Autophagy regulation also works. Chinese Chemical Letters, 2024, 35(6): 109056-. doi: 10.1016/j.cclet.2023.109056
13. [13]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
14. [14]
  Zhilong Xie , Guohui Zhang , Ya Meng , Yefei Tong , Jian Deng , Honghui Li , Qingqing Ma , Shisong Han , Wenjun Ni . A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein. Chinese Chemical Letters, 2024, 35(11): 109584-. doi: 10.1016/j.cclet.2024.109584
15. [15]
  Du Liu , Yuyan Li , Hankun Zhang , Benhua Wang , Chaoyi Yao , Minhuan Lan , Zhanhong Yang , Xiangzhi Song . Three-in-one erlotinib-modified NIR photosensitizer for fluorescence imaging and synergistic chemo-photodynamic therapy. Chinese Chemical Letters, 2025, 36(2): 109910-. doi: 10.1016/j.cclet.2024.109910
16. [16]
  Yuwen Zhu , Xiang Deng , Yan Wu , Baode Shen , Lingyu Hang , Yuye Xue , Hailong Yuan . Formation mechanism of herpetrione self-assembled nanoparticles based on pH-driven method. Chinese Chemical Letters, 2025, 36(1): 109733-. doi: 10.1016/j.cclet.2024.109733
17. [17]
  Yihao Zhang , Yang Jiao , Xianchao Jia , Qiaojia Guo , Chunying Duan . Highly effective self-assembled porphyrin MOCs nanomaterials for enhanced photodynamic therapy in tumor. Chinese Chemical Letters, 2024, 35(5): 108748-. doi: 10.1016/j.cclet.2023.108748
18. [18]
  Yuanzheng Wang , Chen Zhang , Shuyan Han , Xiaoli Kong , Changyun Quan , Jun Wu , Wei Zhang . Cancer cell membrane camouflaged biomimetic gelatin-based nanogel for tumor inhibition. Chinese Chemical Letters, 2024, 35(11): 109578-. doi: 10.1016/j.cclet.2024.109578
19. [19]
  Makhloufi Zoulikha , Zhongjian Chen , Jun Wu , Wei He . Approved delivery strategies for biopharmaceuticals. Chinese Chemical Letters, 2025, 36(2): 110225-. doi: 10.1016/j.cclet.2024.110225
20. [20]
  Jing Zhang , Charles Wang , Yaoyao Zhang , Haining Xia , Yujuan Wang , Kun Ma , Junfeng Wang . Application of magnetotactic bacteria as engineering microrobots: Higher delivery efficiency of antitumor medicine. Chinese Chemical Letters, 2024, 35(10): 109420-. doi: 10.1016/j.cclet.2023.109420

Get Citation

PDF

XML

Metrics

PDF Downloads(10)
Abstract views(873)
HTML views(103)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142